




Alzheimer's disease—revised diagnostic criteria include MRI and PET

Since the publication of the NINCDS-ADRDA criteria for Alzheimer's disease (AD) in 1984, there has been tremendous growth in scientific knowledge that has resulted in the development of new, distinctive, and reliable biomarkers of AD. In light of these advances, a panel of international AD experts has proposed revised diagnostic criteria for AD. A new consensus document containing their research-criteria recommendations was published in *The Lancet Neurology* earlier this year.¹

The new criteria center around early and significant episodic memory impairment with at least one or more abnormal biomarkers among the following¹:

- Structural neuroimaging with MRI
- Molecular neuroimaging with PET
- Cerebrospinal fluid analysis of amyloid β or tau proteins

MRI allows clinicians to recognize medial temporal lobe atrophy, while PET allows for increased diagnostic specificity via visualization of blood flow, glucose metabolism, and protein aggregates of amyloid β and tau.¹



Synarc imaging experts understand what it takes to succeed in a global AD trial

As the world leader in centralized medical-imaging services for global multicenter studies of AD, Synarc is equipped to provide you with diagnostic certainty in your AD clinical trials. We have extensive experience with image acquisition and analysis in AD trials, and we deliver rigorous training and quality control.

"In the past we have provided diagnostic confirmation services for AD clinical trials by primarily excluding other dementias or diseases with MRI," said Joyce Suh, PhD, Scientific Director of Synarc Neurology Clinical Trials Services. "However, with the new criteria that now include structural and molecular imaging biomarkers, we can now confirm the diagnosis with imaging."

Our highly experienced neurology team is composed of neuroradiologists, MRI physicists, image-analysis technicians, and program and project staff. Put us to work on your next AD clinical trial.




AD imaging services

Quantitative and semiquantitative analyses

- Hippocampus volume
- Whole-brain atrophy
- Whole-brain volume
- Ventricle enlargement
- Ventricle volume
- Entorhinal-cortex volume
- Intracranial volume

Qualitative analyses

- Assessment of vascular disease
- Diagnosis and eligibility confirmations
- Independent safety readings



SPOTLIGHT

The high cost of poor subject recruitment

Time is money in clinical development. Considering that a potential blockbuster can lose up to \$8 million daily because of delayed subject recruitment, quick recruitment and long-term retention of study subjects are key to success. According to Gary Velasquez, Synarc President and CEO, "Efficient subject recruitment begins with targeting populations across fewer select sites." Read more in the *Applied Clinical Trials* July 2007 article, "Recruitment done right," available at www.synarc.com.



Gary Velasquez, President and CEO

Join us in November at the Partnering in Oncology conference

Synarc Oncology Director, Dr Caroline Reinhold, will present on the topic of "Imaging Centralization in Oncology" on November 12, 2007, in Philadelphia. For more information and to register, please visit www.regonline.com/63325_143265S.



synarc.com

IMAGING ANALYSIS
SUBJECT RECRUITMENT
BIOCHEMICAL MARKERS


1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol.* 2007;6:734-746.

Synarc experts bring increased confidence to your oncology development program

Synarc has 45 active oncology studies and experience in most types of cancer, including breast, lung, prostate, colorectal, melanoma, and lymphoma. To complement our extensive experience, we have assembled the Synarc Oncology Scientific Advisory Committee (OSAC), an in-house scientific advisory council. OSAC is composed of world-leading authorities in oncology clinical trials. Their expertise covers all major cancer types and includes extensive experience in clinical-trial design, execution, and analysis, as well as regulatory approval.

Members of OSAC have contributed extensively to the advancement of cancer therapies, including the development of the IHP criteria for the treatment of lymphoma and the incorporation of PET-CT in endpoint assessment. They have also participated in numerous scientific and government committees, such as the FDA Oncologic Drugs Advisory Committee.

Your oncology development program is too costly and important to put imaging in the hands of anyone less experienced than the oncology team at Synarc.



Inside

Update on Alzheimer's disease (AD) diagnostic criteria

Synarc provides diagnostic certainty in AD clinical trials

Synarc AD imaging services

Synarc Oncology Scientific Advisory Committee (OSAC)

Top scientists and clinicians at the forefront of oncology research

Phil Schein MD, FRCP, Chief of OSAC, Synarc Clinical Director, Oncology

Anwar R. Padhani, MD, PhD, Associate Medical Director, Oncology

Caroline Reinhold, MD, MSc, Medical Director, Oncology

Ali Guerhazi, MD, Director, Clinical Research; Scientific Director, Oncology

James L. Speyer, MD (breast cancer)

Philippe Solal-Celigny, MD (hematological malignancies)

Mark Green, MD (lung cancer)

Carol Portlock, MD (lymphoma)

Malik Juweid, MD (nuclear medicine and lymphoma)

Susan Slovin, MD, PhD (prostate cancer)